Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, Sanabria Bohorquez SM, Anania VG, Wildsmith KR, Schauer SP, Lee J, Dolton MJ, Ramakrishnan V, Abramzon D, Teng E; Lauriet investigators. Monteiro C, et al. Among authors: sanabria bohorquez sm. Neurology. 2023 Oct 3;101(14):e1391-e1401. doi: 10.1212/WNL.0000000000207663. Epub 2023 Aug 29. Neurology. 2023. PMID: 37643887 Free PMC article. Clinical Trial.
CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab.
Sandoval C, Lee J, Toth B, Nagaraj R, Schauer SP, Hoffman J, Calderon E, Kollmorgen G, Sanabria Bohórquez SM, Monteiro C, Teng E, Hanson JE, Yeh FL, Gutierrez J, Biever A. Sandoval C, et al. Among authors: sanabria bohorquez sm. Alzheimers Dement. 2024 Nov;20(11):7940-7953. doi: 10.1002/alz.14271. Epub 2024 Oct 6. Alzheimers Dement. 2024. PMID: 39369294 Free PMC article.
Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.
Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, Giesen D, Elias SG, Lub-de Hooge MN, Oosting SF, Jalving M, Timens W, Brouwers AH, Kwee TC, Gietema JA, Fehrmann RSN, Fine BM, Sanabria Bohórquez SM, Yadav M, Koeppen H, Jing J, Guelman S, Lin MT, Mamounas MJ, Eastham JR, Kimes PK, Williams SP, Ungewickell A, de Groot DJA, de Vries EGE. Kist de Ruijter L, et al. Among authors: sanabria bohorquez sm. Nat Med. 2022 Dec;28(12):2601-2610. doi: 10.1038/s41591-022-02084-8. Epub 2022 Dec 5. Nat Med. 2022. PMID: 36471036 Free PMC article. Clinical Trial.
GTP1 metabolic stability assessment: A study of the tau PET tracer [18F]GTP1.
Marik J, Rich S, Deshmukh G, Zhang D, Tinianow J, Cai J, Wong S, Bobba S, DeMent K, Liu N, Halladay J, Sanabria-Bohórquez S, Cheruzel L, Khojasteh C. Marik J, et al. Nucl Med Biol. 2023 Sep-Oct;124-125:108386. doi: 10.1016/j.nucmedbio.2023.108386. Epub 2023 Sep 4. Nucl Med Biol. 2023. PMID: 37699300
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, Cassetta E, Woodward M, Boada M, van Dyck CH, Grimmer T, Selkoe DJ, Schneider A, Blondeau K, Hu N, Quartino A, Clayton D, Dolton M, Dang Y, Ostaszewski B, Sanabria-Bohórquez SM, Rabbia M, Toth B, Eichenlaub U, Smith J, Honigberg LA, Doody RS. Ostrowitzki S, et al. Among authors: sanabria bohorquez sm. JAMA Neurol. 2022 Nov 1;79(11):1113-1121. doi: 10.1001/jamaneurol.2022.2909. JAMA Neurol. 2022. PMID: 36121669 Free PMC article. Clinical Trial.
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
Varga A, Soria JC, Hollebecque A, LoRusso P, Bendell J, Huang SA, Wagle MC, Okrah K, Liu L, Murray E, Sanabria-Bohorquez SM, Tagen M, Dokainish H, Mueller L, Burris H. Varga A, et al. Among authors: sanabria bohorquez sm. Clin Cancer Res. 2020 Mar 15;26(6):1229-1236. doi: 10.1158/1078-0432.CCR-19-2574. Epub 2019 Dec 17. Clin Cancer Res. 2020. PMID: 31848189 Clinical Trial.
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, Savage HM, Sampath D, Salphati L, Lin RS, Jin H, Parmar H, Hsu JY, Von Hoff DD, Baselga J. Juric D, et al. Among authors: sanabria bohorquez sm. Cancer Discov. 2017 Jul;7(7):704-715. doi: 10.1158/2159-8290.CD-16-1080. Epub 2017 Mar 22. Cancer Discov. 2017. PMID: 28331003 Free PMC article. Clinical Trial.
31 results